The Academy of Managed Care Pharmacy thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to comment on the Proposed Rule, Medicare Program; CY 2018 Updates to the Quality Payment Program (the Proposed Rule).
AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
Press Release: Lowering the out-of-pocket costs of blood glucose testing strips can improve diabetes patients’ persistence with home monitoring, according to an article in the August 2017 issue of the Journal of Managed Care & Specialty Pharmacy (JMCP).
Conclusions reached in a recent New York Times article on outcomes-based contracting are premature, if not inaccurate, stated Academy of Managed Care Pharmacy (AMCP) CEO Susan A. Cantrell, RPh, CAE, adding, “It’s still the early innings for outcomes-based, or value-based, contracting for prescription drugs, and therefore, too soon to dismiss.”
AMCP supports a coalition of over 20 health care stakeholders committed to aligning 42 CFR Part 2 (Part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.